Chinook Therapeutics, Inc. (KDNY) News
Filter KDNY News Items
KDNY News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
KDNY News Highlights
- For KDNY, its 30 day story count is now at 2.
- Over the past 4 days, the trend for KDNY's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- CHK, MG and PK are the most mentioned tickers in articles about KDNY.
Latest KDNY News From Around the Web
Below are the latest news stories about CHINOOK THERAPEUTICS INC that investors may wish to consider to help them evaluate KDNY as an investment opportunity.
Chinook Therapeutics Presents Data from CHK-336 Phase 1 Trial in Healthy Volunteers and New Insights into the Role of Failed Repair in Chronic Kidney Disease at the 60th European Renal Association (ERA) CongressCHK-336 was generally well tolerated in healthy volunteers (HV) who received single doses up to 500 mg and multiple doses up to 60 mg for 14 daysPharmacokinetics (PK) was well characterized with dose-proportional exposures and a half-life that supports once-daily dosingSuccessful implementation of a novel 13C2-glycolate tracer established proof-of-mechanism of CHK-336 to block hepatic oxalate production in HVsOne serious adverse event (SAE) of anaphylaxis occurred in a multiple ascending dose HV |
Stocks Sport Midday Leads As Busy Week BeginsStocks are modestly higher this afternoon amid hopes of a dovish Fed, with the central bank's policy decision due out Wednesday. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayWe're starting off the week with a breakdown of the biggest pre-market stock movers traders need to know about for Monday morning! |
Why Is Chinook Therapeutics (KDNY) Stock Up 58% Today?Chinook Therapeutics (KDNY) stock is rocketing higher on Monday after the company announced it's being acquired by Novartis AG (NVS). |
Why Is Oncorus (ONCR) Stock Down 27% Today?Oncorus (ONCR) stock is taking a beating on Monday after revealing plans for a vote during an upcoming special shareholder meeting. |
KDNY Stock Alert: Why Short Seller Muddy Waters Is Betting Against ChinookChinook Therapeutics is about to be acquired by Novartis. |
Chinook Therapeutics to Present Updated Data from Zigakibart (BION-1301) Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) at the 60th European Renal Association (ERA) CongressZigakibart Treatment Results in Rapid and Sustained Reductions in IgA and Gd-IgA1 in Patients with IgA Nephropathy Zigakibart produced rapid and sustained reductions in IgA and Gd-IgA1, the pathogenic variant of IgA nephropathy Zigakibart Treatment Results in Rapid and Sustained Reductions in IgA and Gd-IgA1 in Patients with IgA Nephropathy Zigakibart produced rapid and sustained reductions in IgA and Gd-IgA1, the pathogenic variant of IgA nephropathy Zigakibart Treatment Results in Clinically M |
llumina CEO deSouza resigns after proxy battle with Carl IcahnIllumina CEO Francis deSouza has stepped down after a lengthy proxy battle with activist investor Carl Icahn. Yahoo Finance health care reporter Anjalee Khemlani breaks down the timeline of events, while also commenting on Novartis' $3.5 billion acquisition deal with Chinook Therapeutics. |
Stocks to Watch Monday: Biogen, Illumina, Oracle**↗️** [**Biogen (BIIB)**](https://www.wsj.com/market-data/quotes/BIIB): The biotech company's shares rose 1.3% after an advisory committee [recommended the Food and Drug Administration approve Leqembi](https://investors. |
Trending tickers: Glencore | Novartis | Frasers | UBSThe latest investor updates on stocks that are trending on Monday. |